Research Topics
Species | Ramon CacabelosSummaryAffiliation: EuroEspes Biomedical Research Center Country: Spain Publications
| Collaborators
|
Detail Information
Publications
Pharmacogenomics in Alzheimer's diseaseRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, La Coruna, Spain
Mini Rev Med Chem 2:59-84. 2002..Furthermore, the pharmacogenomics of AD may contribute in the future to optimise drug development and therapeutics, increasing efficacy and safety, and reducing side-effects and unnecessary costs...- Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implicationsRamon Cacabelos
Department of Clinical Neuroscience, EBIOTEC, EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
Neurol Res 25:567-80. 2003..In this regard, cerebrovascular dysfunction should be considered a potential therapeutic target in dementia... - Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular componentRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders, EuroEspes Biotechnology EBIOTEC, Coruna, Spain and Department of Biotechnology and Genomics, Camilo José Cela University, Madrid, Spain
Neurol Res 26:459-80. 2004.... - Pharmacogenomics for the treatment of dementiaRamon Cacabelos
From the EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, La Coruna, Spain
Ann Med 34:357-79. 2002..The pharmacogenomics of AD may contribute in the future to optimise drug development and therapeutics, increasing efficacy and safety, and reducing side-effects and unnecessary costs... - Genomics and phenotypic profiles in dementia: implications for pharmacological treatmentR Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders, EuroEspes Biotechnology EBIOTEC, Coruna, Spain
Methods Find Exp Clin Pharmacol 26:421-44. 2004.... - Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementiaRamon Cacabelos
EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Madrid, Spain
Pharmacogenomics 5:1049-105. 2004..All these genotypic and phenotypic variations bring about important consequences for the pharmacogenomics of AD... - A pharmacogenomic approach to Alzheimer's diseaseR Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders, La Coruna, Spain
Acta Neurol Scand Suppl 176:12-9. 2000..All these data suggest that the therapeutic outcome in AD exhibits a genotype-specific pattern, and that a pharmacogenomic approach to AD might be a valuable strategy for drug development and monitoring... - The application of functional genomics to Alzheimer's diseaseRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, Coruna, Spain
Pharmacogenomics 4:597-621. 2003..Consequently, the understanding of functional genomics in AD will foster productive pharmacogenomic studies in the search for effective medications and preventive strategies in AD... 
Pharmacogenomics in Alzheimer's diseaseRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
Methods Mol Biol 448:213-357. 2008..The incorporation of pharmacogenetic/pharmacogenomic protocols to AD research and clinical practice can foster therapeutics optimization by helping to develop cost-effective pharmaceuticals and improving drug efficacy and safety...- Pharmacogenomics and therapeutic prospects in dementiaRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, Coruna, Spain
Eur Arch Psychiatry Clin Neurosci 258:28-47. 2008.... 
Resting-state network disruption and APOE genotype in Alzheimer's disease: a lagged functional connectivity studyLeonides Canuet
EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Corunna, Spain
PLoS ONE 7:e46289. 2012..This study aimed at identifying spatial patterns and effects of APOE genotype on resting-state oscillations and functional connectivity in patients with AD, using a physiological connectivity index called "lagged phase synchronization"...- Molecular genetics of Alzheimer's disease and agingRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, La Coruna, Spain
Methods Find Exp Clin Pharmacol 27:1-573. 2005..Furthermore, the pharmacogenomics of Alzheimer's disease may contribute in the future to optimize drug development and therapeutics, increasing efficacy and safety, and reducing side-effects and unnecessary costs... - Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injuryX Anton Alvarez
Department of Neuropharmacology, EuroEspes Biomedical Research Center, Santa Marta de Babío, Bergondo, A Coruna, Spain
J Neural Transm 115:683-92. 2008..Results of this exploratory study suggest that Cere might improve the functional recovery after brain injury and encourage the conduction of further controlled clinical trials... - Genomics and pharmacogenomics of brain disordersRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Bergondo, Corunna, Spain
Curr Pharm Biotechnol 13:674-725. 2012..The incorporation of genomic medicine procedures and pharmacogenomics into clinical practice, together with educational programs for the correct use of medication, must help to optimize therapeutics in CNS disorders... - Decreased levels of serum nitric oxide in different forms of dementiaLola Corzo
Department of Clinical Biochemistry, EuroEspes Biomedical Research Center, Santa Marta de Babío s n, 15166 Bergondo, La Coruna, Spain
Neurosci Lett 420:263-7. 2007..Our data suggest that NOx may contribute to the pathogenesis of dementia through a process mediated by HDL-cholesterol... - Genetic variation and pharmacogenomics in Alzheimer diseaseRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders, Spain
Seishin Shinkeigaku Zasshi 105:47-67. 2003 - Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depressionRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
Methods Find Exp Clin Pharmacol 29:1-91. 2007..The incorporation of pharmacogenetic/pharmacogenomic protocols to AD research and clinical practice can foster therapeutics optimization by helping to develop cost-effective pharmaceuticals and improving drug efficacy and safety... - Pharmacogenomics and therapeutic strategies for dementiaRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, 15165 Bergondo, Coruna, Spain
Expert Rev Mol Diagn 9:567-611. 2009.... - Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogeneticsRamon Cacabelos
Institute for CNS Disorders, EuroEspes Biomedical Research Center, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Bergondo, Coruna, Spain
Curr Alzheimer Res 4:479-500. 2007..From these data, it can be postulated that pharmacogenetic and pharmacogenomic factors are responsible for 75-85% of the therapeutic response in AD patients treated with conventional drugs... - Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusionX A Alvarez
EuroEspes Biomedical Research Center, A Coruna, Barcelona, Spain
Methods Find Exp Clin Pharmacol 21:633-44. 1999.... - Genomics and pharmacogenomics of schizophreniaRamon Cacabelos
EuroEspes Biomedical Research Center, 15165 Bergondo, Coruna, Spain
CNS Neurosci Ther 17:541-65. 2011..Consequently, the incorporation of pharmacogenomic procedures both to drugs in development and drugs on the market would help to optimize therapeutics in SCZ and other central nervous system (CNS) disorders... - Genomics of Dementia: APOE- and CYP2D6-Related PharmacogeneticsRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, 15165 Bergondo, Spain
Int J Alzheimers Dis 2012:518901. 2012..APOE and CYP2D6 may cooperate, as pleiotropic genes, in the metabolism of drugs and hepatic function. The introduction of pharmacogenetic procedures into AD pharmacological treatment may help to optimize therapeutics... - Influence of pharmacogenetic factors on Alzheimer's disease therapeuticsRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Spain
Neurodegener Dis 5:176-8. 2008..The incorporation of pharmacogenetic protocols into AD research and clinical practice can foster therapeutics optimization by improving drug efficacy and safety... - Pharmacogenetic basis for therapeutic optimization in Alzheimer's diseaseRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
Mol Diagn Ther 11:385-405. 2007.... - Pharmacogenomic protocols in CNS disorders and dementiaRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Bergondo, Coruna, Spain
Neurodegener Dis 7:167-9. 2010.... - Genomics and pharmacogenomics of dementiaRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Bergondo, Coruna, Spain
CNS Neurosci Ther 17:566-76. 2011.... - Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamicsX A Alvarez
EuroEspes Biomedical Research Center, A Coruna, Spain
Methods Find Exp Clin Pharmacol 22:585-94. 2000..These effects of anapsos were more marked in demented patients with mild mental deterioration and/or with dementia of the Alzheimer type... - Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer diseaseAntón Alvarez
EuroEspes Biomedical Research Center, 15166 A Coruña, Spain
Neurobiol Aging 28:533-6. 2007..In addition, the combined determination of TNF-alpha and IGF-I might be useful to monitor anti-inflammatory and/or neurotrophic drug effects in AD... - Pharmacogenomics and therapeutic prospects in Alzheimer's diseaseRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, Coruna, Spain
Expert Opin Pharmacother 6:1967-87. 2005.... - Pharmacogenomics of antipsychotics efficacy for schizophreniaRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Bergondo, Coruna, Spain
Psychiatry Clin Neurosci 65:3-19. 2011.... - A novel mutation in the predicted TM2 domain of the presenilin 2 gene in a Spanish patient with late-onset Alzheimer's diseaseJ I Lao
Department of Clinical and Molecular Genetics, Basic and Clinical Neurosciences Research Center, EuroEspes Biomedical Research Center, A Coruna, Spain
Neurogenetics 1:293-6. 1998..In summary, we report here the first mutation in a presenilin gene in a Spanish AD case, which is the third mutation detected for the PS-2 gene... - Microglial activation induced by factor(s) contained in sera from Alzheimer-related ApoE genotypesV R Lombardi
EuroEspes Biomedical Research Center, Division of Biotechnology, Santa Marta de Babío, La Coruna, Spain
J Neurosci Res 54:539-53. 1998..These results strongly suggest that primary in vitro microglial cell cultures can be used as a screening model to test human sera as well as the effect of new potential drugs aimed at down-regulating microglia activation... - Association between APOE epsilon4 allele and increased expression of CD95 on T cells from patients with Alzheimer's diseaseV R M Lombardi
EBIOTEC, Biotechnology Division, La Coruna, Spain
Methods Find Exp Clin Pharmacol 26:523-9. 2004..Hyperexpression of Fas mRNA and surface Fas receptor on CD45RO(+) T lymphocytes may explain the occurrence of inflammatory cellular infiltrates in the CNS of AD patients... - In vitro regulation of rat derived microgliaValter R M Lombardi
Ebiotec Biotechnology Division, La Coruna, Spain
Neurotox Res 5:201-12. 2003..These findings suggest that resting ramified microglial cells with neurotrophic activity can be induced with the combination of BME medium and small amounts of extracellular matrix growth promoters... - Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory studyX Anton Alvarez
EuroEspes Biomedical Research Center, Santa Marta de Babia, 15166 Bergondo, A Coruna, Spain
Int Clin Psychopharmacol 18:271-8. 2003..These promising preliminary results suggest that Cerebrolysin might be a useful treatment to improve the recovery of patients with traumatic brain damage, and encourage the conduction of confirmatory clinical trials... - 19/20 kDa low molecular weight serum protein pattern: a novel potential biochemical prognostic marker for different types of dementiaV R Lombardi
Department of Biotechnology, EuroEspes, Biomedical Research Center, La Coruna, Spain
Neurosci Lett 260:61-4. 1999..The findings suggest that two proteins of 19 and 20kDa molecular weight, respectively, might be associated with disease progression in different types of dementia... - Plasticity of Congo red staining displayed by subpopulations of neurons within the rat central nervous systemJ J Miguel-Hidalgo
Department of Basic Neuroscience, EuroEspes Biomedical Research Center, Santa Marta de Babío, E 15166 Bergondo, La Coruna, Spain
Cell Tissue Res 293:75-86. 1998..Therefore, it is proposed that neurons labelled with the present Congo red technique might be in a reversible degenerative state or represent a particular physiological state in some areas of the central nervous system... - Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in ratsX A Alvarez
EuroEspes Biomedical Research Center, A Coruna, Spain
Methods Find Exp Clin Pharmacol 21:535-40. 1999..01 vs. CDP0) in a dose-related manner. Based on these results, it was concluded that citicoline exerts antiapoptotic, neuroprotective and antiamnesic effects in conditions of neurodegeneration induced by A beta 4 plus hypoperfusion... - Neuropeptide dietary supplement N-PEP-12 enhances cognitive function and activates brain bioelectrical activity in healthy elderly subjectsX A Alvarez
Department of Neuropharmacology, EuroEspes Biomedical Research Center, Santa Marta de Babío, Bergonodo, A Coruna, Spain
Methods Find Exp Clin Pharmacol 27:483-7. 2005..Taken together, these data suggest that N-PEP-12 might be a reliable dietary supplement to be investigated for improving and, perhaps, maintaining brain function among healthy older adults... - Histamine function in brain disordersL Fernandez-Novoa
Department of Neurobiology, Institute for CNS Disorders, EuroEspes Biomedical Research Center, Bergondo 15166, La Coruna, Spain
Behav Brain Res 124:213-33. 2001..Peripheral cellular studies in health and disease, molecular studies on receptors and in vivo pharmacological studies may help us to better understand the function of the histaminergic system in health and disease... - Effects of Cerebrolysin on in vitro primary microglial and astrocyte rat cell culturesV R Lombardi
Biotechnology Division, EuroEspes, Basic and Clinical Neurosciences Research Center, La Coruna, Spain
Methods Find Exp Clin Pharmacol 21:331-8. 1999.... - Enhancement in immune function and growth using E-JUR-94013 supplementationV R M Lombardi
EuroEspes Biotechnology, Santa Marta de Babío, La Coruna, Spain
Methods Find Exp Clin Pharmacol 24:573-8. 2002..Both effects resulted in better pig growth, demonstrating that E-JUR-94013 can also be used as a natural growth promoter and an immune enhancer... - A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's diseaseX A Alvarez
Euroespes Biomedical Research Centre, Santa Maria de Babio, Bergondo, La Coruna, Spain
Eur J Neurol 13:43-54. 2006..The percentage of patients reporting adverse events was similar across all study groups. Cere treatment was well tolerated and led to significant, dose-dependent improvement of cognition and global clinical impression... - Effects of FR-91 on immune cells from healthy individuals and from patients with non-Hodgkin lymphomaV R M Lombardi
Departamento de Inmunología Celular, Euroespes Biotecnologia, La Coruna, 15166 Bergondo, Spain
J Biomed Biotechnol 2009:187015. 2009..In conclusion FR-91 seems to affect lymphocyte subpopulations, in vitro cytokine production, as well as mitogen-induced lymphocyte activation in a dose-dependent manner in both healthy individuals and NHL patients...